AIM’s Clinical Strategy under the Incumbent Board is Aimless and Flawed and has Resulted in Failure AIM’s strategy under the incumbent Board is all talk and no substance. It involves touting numerous ...

The results of an audit on Arlington Independent Media are out, revealing substantial gaps and errors in how the nonprofit handled some $2 million in county-provided funds. The audit report appears to ...

AIM board members addressing the public at a virtual meeting in March 2024 (via Arlington Independent Media/Zoom) Updated 3/27 After an intense several weeks involving a county audit, a board ...

Warns AIM Shareholders of Activist Group’s Plan to Reimburse Individuals More Than $5 Million for Failed Litigation Against AIM, in Addition to Any Expenses Incurred in Connection With This Year’s ...

AIM Immunotech (AIM) stockholder Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, issued a statement in connection with the incumbent Board of Directors of ...

Highlights Evidence of Group’s Scheme to Have Jorgl Serve as the “Face of the Activist” to Help Them “Get Control” Without Paying a Premium to All Shareholders Group Concealed that Its Campaign Was ...

Highlights Significant Progress Made in Recent Years – and Especially Over Past 18 Months – in Repurposing Lead Drug Ampligen in Oncology to Benefit Patients and All Shareholders Calls on Shareholders ...

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation highlighting why shareholders should NOT elect the four director candidates ...